Friday, April 12, 2013 - 07:29

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces today that new preclinical data for two proprietary programs were presented at the Molecular Pattern Recognition Receptors meeting and the American Association for Cancer Research (“AACR”) annual meeting:

  • Dr Morel, Chief Business Officer of Innate Pharma, presented “Therapeutic Antibody against Toll-Like Receptor 3 for the Treatment of Inflammation”, a comprehensive review of the IPH33 program, today, at the “Molecular Pattern Recognition Receptors” meeting in Boston, MA.

  • Dr Sicard, Senior Director, R&D at Innate Pharma, presented a poster on IPH41 program: “Novel therapeutic and diagnostic antibodies against KIR3DL2, a unique tumor antigen overexpressed on subtypes of T Cell Lymphomas” on Wednesday April 10, 2013 at the AACR meeting in Washington D.C.


The full poster and presentation are available on the Company’s website in the section “Products in development”.

AttachmentSize
PR in English33.49 KB
CP en français33.68 KB